

**COPY**

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/527,598	Pierrette Gaudreau	BCF-001


INTERNATIONAL APPLICATION NO.
-------------------------------

PCT/CA03/01418

I.A. FILING DATE	PRIORITY DATE
09/17/2003	09/18/2002

051414

GOODWIN PROCTER LLP  
 PATENT ADMINISTRATOR  
 EXCHANGE PLACE  
 BOSTON, MA 02109-2881



CONFIRMATION NO. 7604

371 FORMALITIES LETTER



\*OC000000021210127\*

Date Mailed: 12/04/2006

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

**For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:**

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.  
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

**If you are not using EFS-Web to submit your reply, you must include a copy of this notice.**

DONNA S GREENE

Telephone: (703) 308-9140 EXT 222

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/527,598	PCT/CA03/01418	BCF-001

# **PCT 371 Routing Sheet**

## **APPLICATION**

**IFW DocCode - SEQREQ**

**Index using Current Date**


**10/527,598**

**TO BE DELIVERED TO:**  
**Tech Center Scanning**

### **Sequence Rule Compliance Review Item**

<b>X</b>	CRF, paper copy of sequence listing, and statement that both are same missing
	CRF contains error(s) according to STIC Report
	CRF damaged or unreadable according to STIC Report
	CRF transferred from prior application is not compliant

**Place an "X" in the appropriate box**

  
Cecilia J. Tsang  
Supervisory Patent Examiner  
Technology Center 1600

**Comment Sheet**

**APPLICATION SERIAL NUMBER**

**10/527,598**


**DOES NOT COMPLY WITH THE  
SEQUENCE RULES. See reasons below.**

**The claims are drawn to sequences comprising more than four contiguous amino acids. The sequence listing and CRF are missing.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h1>TRANSMITTAL FORM</h1> <p><i>(to be used for all correspondence after initial filing)</i></p>	Application Number	10/527,598-Conf. #7604
	Filing Date	September 17, 2003
	First Named Inventor	Pierrette Gaudreau
	Art Unit	1654
	Examiner Name	C. Bradley
Total Number of Pages in This Submission	Attorney Docket Number	BCF-001

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement and Form PTO/SB/08 <input type="checkbox"/> Copy of cited reference B1  <input type="checkbox"/>	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____  <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input checked="" type="checkbox"/> Certificate of Mailing <input checked="" type="checkbox"/> Return Receipt Postcard <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): -Copies of Identical Notifications to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures mailed on November 14, 2006 and mailed on December 4, 2006 (4 pages each) -Paper (55 pages) and Computer Readable Copy (1 disk) of Sequence Listing -Submission of Paper Copy and/or Computer Readable Copy of Sequence Listing for Invention Containing Nucleotide and/or Amino Acid Sequence (2 pages)

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	GOODWIN PROCTER LLP	
Signature		
Printed name	Randall D. Morin	
Date	February 5, 2007	Reg. No. 58,312

Application No. (if known): 10/527,598


Attorney Docket No.: BCF-001

**Certificate of Mailing under 37 CFR 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on February 5, 2007  
Date

  
Signature

Linda A. Geraigery

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 570-1000

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

- Transmittal Form (1 page)
- Amendment and Response to Notification to Comply (13 pages)
- Copies of Identical Notifications to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures mailed on November 14, 2006 and on December 4, 2006 (4 pages each)
- Information Disclosure Statement (2 pages)
- Form PTO/SB/08 (1 page) and copy of reference B1
- Paper (55 pages) and Computer Readable Copy (1 disk) of Sequence Listing
- Submission of Paper Copy and/or Computer Readable Copy of Sequence Listing for Invention Containing Nucleotide and/or Amino Acid Sequence (2 pages)
- Certificate of Mailing (1 page)
- Return Receipt Postcard